Vitamin D Intervention Trial in Healthy Chinese, Phase II

NCT ID: NCT01998763

Last Updated: 2016-01-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 448 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-11-30
• Study Completion Date: 2015-12-31

Brief Summary

This is a double-blind, randomized, placebo-controlled trial. Based on inclusion and exclusion criteria, 400 eligible volunteers, who were 20-45 years, with 25-hydroxyvitamin D between 12.5-50 nmol/L and BMI between 18.5-28 kg/m2, were enrolled and randomly assigned to placebo or 2000 IU/d vitamin D3 arm, after taking placebo for one week. The study protocol was approved by the Ethics Committee of Huadong Hospital Affiliated to Fudan University, Shanghai and all participants provided written informed consents.In this 2-arm RCT we aimed to systematically investigate the effect of:

1. vitamin D3 supplement on serum 25(OH)D levels and the modifying factors;

2. genetic and non-genetic variants on vitamin D bioavailability;

3. vitamin D3 supplementation on metabolic profiles and circulating bone-turnover markers

Detailed Description

At present time, the Recommended Dietary Allowance (RDA) and the tolerable upper intake level (UL) for vitamin D are 200 IU/day and 800 IU/day for Chinese aged 11-50 years, respectively. On the other hand, the RDA and UL for vitamin D for the same age group in USA are 600IU/day and 4000IU/day, respectively. Indeed, recent epidemiological studies suggested that serum 25-hydroxyvitamin D [25(OH)D] concentration ≥75 nmol/L appeared to be optimal for preventing cardiometabolic diseases and improving bone health. To achieve this goal, a daily intake of 1000 IU or equivalent amount from other sources, is needed, which is twice as much as the RDA recommended by Chinese Nutrition Society. Except for those individuals with hypersensitive conditions, daily intake less than 10,000 IU of vitamin D have not shown overt adverse effects based upon the studies conducted in Western populations.

Since vitamin D metabolic rate and its relationship with health outcomes may vary across different ethnical groups and most available data so far were from Caucasians populations, it remains to be elucidated whether the findings from Western population could apply directly to Asian peoples like Chinese. Recently, our group has conducted the first relatively large-scale study in Asian to evaluate the association between 25(OH)D and risk of metabolic syndrome. It was found that the geometric mean of plasma 25(OH)D in these Chinese adults aged 50-70 years from Beijing and Shanghai (n=3210) was 40.36 nmol/l and percentage of vitamin D deficiency [25(OH)D <50 nmol/l] and insufficiency (50 ≤ 25(OH)D < 75 nmol/l) were 69.2% and 24.4%, respectively. Comparing the lowest with the highest 25(OH)D quintile (≤28.7 nmol/l vs. ≥57.7 nmol/l), the odds ratio for metabolic syndrome (MetS) was 1.52 (95% CI 1.17-1.98, P for trend = 0.0002), after multiple adjustment. Significant inverse associations also existed between 25(OH)D and most of MetS components, plus HbA1c. Moreover, low plasma 25(OH)D level was found to be associated with increased insulin resistance index (homeostasis model assessment of insulin resistance, HOMA-IR) in those overweight and obese individuals (BMI ≥24 kg/m2),. (Lu et al., Diabetes Care, 2009). According to the data from 2002 China National Nutrition Survey, high prevalence of vitamin D deficiency also exited in Chinese children aged 1-3 years and approximate 82% of them had circulating 25(OH)D ≤ 50nmol/L. In consistent with our finding, a report from a population-based Korea study showed that the association between 25(OH)D and insulin resistance was modified by BMI status (Choi et al.,The Journal of Nutrition,2011).

In our recent genetic study, it was found that genetic variants at GC and NADSYN1/DHCR7 were significantly associated with circulating 25(OH)D levels while marginal association between CYP2R1-rs2060793 and 25(OH)D levels was observed only in the Shanghai subpopulation (Lu et al., Human Genetics 2011). In addition, we developed a genetic risk score (GRS) to evaluate the combined effect of three SNPs (rs4588, rs1790349 and rs2060793) from GC, NADSYN1/DHCR7 and CYP2R. Notably, the average plasma 25(OH)D concentration in individuals with 5-6 risk allele was 11.4 nmol/l lower than those without risk allele. Indeed, previous studies suggested that intake of 100 IU vitamin D could only raise circulating 25(OH)D by 2.5 nmol/l, implicating that 450 IU of extra vitamin D is required for these high risk individuals. The possible interpretations for such a high prevalence of poor vitamin D nutrition among Chinese may be due to the factors: (1) unlike United States and other Western countries, few, if any, vitamin D enriched or fortified foods are available in China; (2) Chinese, particularly women, like to have pale skin color, who therefore frequently utilize sunscreen and umbrella to prevent sun exposure. (3) approximate 318 million people are living in Heilongjiang, Shaanxi, Jilin, Shanxi, Liaoning, Qinghai, Gansu, Inner Mongolia, Xinjiang, and Hebei provinces, the areas with latitude N37°, which was previously showed to prevent skin synthesizing sufficient vitamin D during winter time. Collectively, all of these factors suggest that large proportions of Chinese may suffer vitamin D insufficiency or deficiency whereas the current RDA in China might be too low to provide adequate vitamin D for people's health. In order to fill up this gap, therefore, it is essential to study the bioavailability following vitamin D intervention and also identify the effects of genetic variants and other factors on vitamin D metabolism and associated health outcomes. Ultimately, the current study will provide important evidence for establishing optimal vitamin D requirement for Chinese people.

Conditions

Vitamin D Deficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

5 placebo pills per day, 20 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,

2000 IU/d Vitamin D3

5 vitamin D3 pills per day, 20 weeks

Group Type: EXPERIMENTAL

Vitamin D3

Intervention Type: DIETARY_SUPPLEMENT

Vitamin D3 2000 IU per day

Interventions

Placebo

placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,

Intervention Type: DIETARY_SUPPLEMENT

Vitamin D3

Vitamin D3 2000 IU per day

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Age: 20-45 years. with vitamin D deficiency (12.5 ≤ 25(OH)D < 50 nmol/l)

Exclusion Criteria

• BMI < 18.5 kg/m2, or BMI ≥ 25 kg/m2
• Total intake of calcium from diet or supplements >1200mg/d, or fasting serum calcium level ≥2.75 mmol/l
• Participating in other clinical studies within previous 3 months
• Taking vitamin D supplements within previous 3 months
• Using medications that may affect vitamin D metabolism in previous 3 months;
• Concomitant with clinical conditions, like liver dysfunction (serum alanine transaminase (ALT) ≥40 U/L; and/or aspartate transaminase (AST) ≥40 U/L; Glutamyl transpeptidase （GGT）≥50 U/L; serum creatinine < 50 or > 120 µmol/L; urea nitrogen (UN) < 7 or > 18 mg/dl, and/or urine acid <90 or >420 µmol/L; which may affect vitamin D metabolism;
• History of drug or alcohol abuse (>40 g/d)
• Women during pregnancy or lactation
• Individuals with mental disorders or current use of antidepressants, the conditions which may affect him or her understanding and unwillingness to the intervention;
• Having clinically diagnosed AIDS, hepatitis A, hepatitis B, tuberculosis and other infectious diseases.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chinese Academy of Sciences

OTHER_GOV

Sponsor Role: lead

Responsible Party

Xu Lin

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Xu Lin, PhD

Role: PRINCIPAL_INVESTIGATOR

Institute for Nutritional Sciecnes, Chinese Acadamy of Sciences

Locations

Institute for Nutritional Sciecnes, Chinese Acadamy of Sciences

Shanghai, , China

Countries

China

References

Yao P, Sun L, Xiong Q, Xu X, Li H, Lin X. Cholecalciferol Supplementation Promotes Bone Turnover in Chinese Adults with Vitamin D Deficiency. J Nutr. 2018 May 1;148(5):746-751. doi: 10.1093/jn/nxy032.

Reference Type: DERIVED

PMID: 29897564 (View on PubMed)

Yao P, Sun L, Lu L, Ding H, Chen X, Tang L, Xu X, Liu G, Hu Y, Ma Y, Wang F, Jin Q, Zheng H, Yin H, Zeng R, Chen Y, Hu FB, Li H, Lin X. Effects of Genetic and Nongenetic Factors on Total and Bioavailable 25(OH)D Responses to Vitamin D Supplementation. J Clin Endocrinol Metab. 2017 Jan 1;102(1):100-110. doi: 10.1210/jc.2016-2930.

Reference Type: DERIVED

PMID: 27768857 (View on PubMed)

Other Identifiers

KSCX2-EW-R-10

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

KSCX2-EW-R-10-VDII

Identifier Type: -

Identifier Source: org_study_id